Search results
Showing 1 to 15 of 56 results for gynaecological cancer
In development Reference number: GID-TA11424 Expected publication date: 17 June 2026
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2: CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 14 July 2026
home. Podcasts 27 May 2026 Endometriosis fertility care and gynaecological cancer guidance In this episode of NICE Talks, we're covering...
Endometriosis fertility care and gynaecological cancer guidance
Home News Podcasts Endometriosis fertility care and gynaecological cancer guidance Podcasts 01 May 2026 Listen About this episode For the
Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
- Overview
- Introduction
- Recommendations organised by site of cancer
- Recommendations on patient support, safety netting and the diagnostic process
- Recommended actions organised by symptom and findings of primary care investigations
- Terms used in this guideline
- Recommendations for research
- Rationale and impact
ovarian cancer The treatment uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells...
Maximal cytoreductive surgery for advanced ovarian cancer (HTG668)
Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.
View recommendations for HTG668Show all sections
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
- Update information
Evidence-based recommendations on laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer. This involves removing the uterus through several small cuts in the abdomen (keyhole surgery), with the aid of an internal telescope and camera.
View recommendations for HTG229Show all sections
Sections for HTG229
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)
This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77
condition Cancer Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer? Medicines to reduce the...